Evaluation of pulmonary arterial hypertension

Current Opinion in Cardiology

Volumn 19, Issue 6, 2004, Pages 575-581

  Galiè, Nazzareno ^a   Manes, Alessandra ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Classification; Diagnosis; Hypertension; Prognosis; Pulmonary

Indexed keywords

ARTERIAL GAS; BLOOD GAS ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; EVALUATION; EXERCISE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC MONITORING; HUMAN; LUNG FUNCTION TEST; LUNG SCINTISCANNING; LUNG VASCULAR RESISTANCE; LUNG VENTILATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RELIABILITY; REVIEW; RISK ASSESSMENT;

ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY ARTERY; RESPIRATORY FUNCTION TESTS;

EID: 8344252688     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000142066.14966.85     Document Type: Review

References (50)

1. Simonneau G, Galie N, Rubin L, et al.: Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:S5-S12. This paper provides the first official presentation of the new Venice clinical classification of pulmonary hypertension. All the aspects related to the changes compared to the previous classifications are discussed in depth. The Venice classification will represent the reference for all future studies in pulmonary hypertension.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al.: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
3. Humbert M, Morrell N, Archer S, et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:S13-S24. The more recent understandings on the pathobiology of PAH are summarized in this article. The molecular pathways leading biologic changes are analyzed. Hypotheses and future research directions are also provided.
4. Barst R, McGoon M, Torbicki A, et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:S40-S47. Diagnosis and assessment of pulmonary hypertension are discussed. The role of any diagnostic procedure is analyzed and put into context. A diagnostic algorithm is also proposed.
5. Galie N, Seeger W, Naeije R, et al.: Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension, J Am Coll Cardiol 2004, 43:381-S88. Analysis of the multiple randomized controlled trials performed in patients with PAH, An evidence-based treatment algorithm is proposed and regulatory approvals for any compound are presented.
6. Hoeper M, Oudiz R, Peacock A, et al.: End-points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004, 43:48S-55S. The paper provides an analysis on the endpoints and designs of clinical trials in patients with PAH, The relative importance of any investigative procedure is discussed.
7. Hatano S, Strasser T: Primary Pulmonary Hypertension. Geneva: World Health Organization; 1975.
8. Newman JH, Trembath RC, Morse JA, et al.: Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004, 43:S33-S39. An updated discussion of all aspects of genetics in PAH,
9. Pietra GG, Capron F, Stewart S, et al.: Pathologic assessment of vasculopahies in pulmonary hypertension. J Am Coll Cardiol 2004, 43:S25-S32. A discussion of traditional pathologic aspects of PAH. A new pathologic classification is proposed,
10. Rich S, Dantzker DR, Ayres SM, et al.: Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987, 107:216-223.
11. Ahearn GS, Tapson VF, Rebeiz A, et al.: Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002, 122:524-527.
12. Borgeson DD, Seward JB, Miller FA Jr, et al.: Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 1996, 9:832-837.
13. McQuillan BM, Picard MH, Leavitt M, et al.: Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001, 104:2797-2802.
14. Mukerjee D, St George D, Knight C, et al.: Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004, 43:461-466. Experience on echocardiography as a screening tool in patients with systemic sclerosis is presented. The data were collected in a large patient population.
15. Hinderliter AL, Willis PW, Barst RJ, et al.: Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 1997, 95:1479-1486.
16. Galie N, Hinderliter AL, Torbicki A, et al.: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:1380-1386. This paper presents the data on the first double-blind, randomized controlled study on the effect of a therapeutic intervention on the echocardiographic variables in patients with PAH.
17. Pauwels RA, Buist AS, Calverley PM, et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
18. Kazerooni EA, Martinez FJ, Flint A, et al.: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977-983.
19. Fedullo PF, Auger WR, Kerr KM, et al.: Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001, 345:1465-1472.
20. Dartevelle P, Fadel E, Mussot S, et al.: Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004, 23:637-648. Updated and complete review on CTEPH. Clinical, diagnostic, and therapeutic insights are provided.
21. Resten A, Maitre S, Capron F, et al.: Pulmonary hypertension: CT findings in pulmonary veno-occlusive disease. J Radiol 2003, 84:1739-1745.
22. Ley S, Kreitner KF, Fink C, et al.: Assessment of pulmonary hypertension by CT and MR imaging. Eur Radiol 2004, 14:359-368. Updated and complete review on CT and MR imaging in pulmonary hypertension. Future trends are also provided.
23. Rich S, Kieras K, Groves B, et al.: Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986, 8:1307-1311.
24. Albrecht T, Blomley MJ, Cosgrove DO, et al.: Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999, 353:1579-1583.
25. Naeije R: Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003, 133:163-169.
26. Miyamoto S, Nagaya N, Satoh T, et al.: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Grit Care Med 2000, 161:487-492.
27. Wensel R, Opitz CF, Anker SD, et al.: Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002, 106:319-324.
28. Galie N, Manes A, Branzi A: The new clinical trials on pharmacological treatment in pulmonary arterial hypertension, Eur Respir J 2002, 20:1037-1049.
29. Peacock A, Naeije R, Galie N, et al.: End-points for clinical trials in pulmonary arterial hypertension: the way forward, Eur Respir J 2004, 23:947-953. Provides an analysis on the endpoints and designs of clinical trials in patients with PAH, The relative importance of any investigative procedure is discussed.
30. Guyatt GH, Sullivan MJ, Thompson PJ, et al.: The 6-minute walk: a new measure of exercise capacity in patients with chronic failure. Can Med Assoc J 1985, 132:919-923.
31. Barst RJ, McGoon M, Mc Laughlin W, et al.: Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:2119,2125.
32. Barst RJ, Langleben D, Frost A, et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 169:441-447.
33. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
34. Sitbon O, Humbert M, Jagot JL, et al.: Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998, 12:265-270.
35. Sitbon O, Humbert M, loos V, et al.: Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? Am J Respir Crit Care Med 2003, 167:A440.
36. Weir EK, Rubin LJ, Ayres SM, et al.: The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989, 140:1623-1630.
37. Galie N, Ussia G, Passarelli P, et al.: Role of pharmacologie tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995, 75:55A-62A.
38. McLaughlin W, Genthner DE, Panella MM, et al.: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998, 338:273-277.
39. Nootens M, Kaufman E, Rich S: Short-term effectiveness of nifedipine in secondary pulmonary hypertension. Am J Cardiol 1993, 71:1475,1476.
40. McLaughlin W, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
41. Sitbon O, Humbert M, Nunes H, et al.: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
42. Eysmann SB, Palevsky HI, Reichek N, et al.: Two-dimensional and Dopplerechocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989, 80:353-360.
43. Raymond RJ, Hinderliter AL, Willis PW, et al.: Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension, J Am Coll Cardiol 2002, 39:1214-1219.
44. Yeo TC, Dujardin KS, Tei C, et al.: Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998, 81:1157-1161.
45. Ratfy O, Azarian R, Brenot F, et al.: Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996, 93:484-488.
46. Voelkel MA, Wynne KM, Badesch DB, et al.: Hyperuricemia in severe pulmonary hypertension. Chest 2000, 117:19-24.
47. Nagaya N, Nishikimi T, Uematsu M, et al.: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
48. Torbicki A, Kurzyna M, Kuca P, et al.: Detectable serum cardiac troponin T as a marker of poor progriosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003, 108:844-848. Provides evidence for ongoing myocardial damage in patients with PAH as assessed by serum cardiac troponin T. The prognostic value of this biomarker is also shown.
49. Nootens M, Kaufmann E, Rector T, et al.: Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995, 26:1581-1585.
50. Rubens C, Ewert R, Halank M, et al.: Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001, 120:1562-1569.